©2024 Stanford Medicine
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Not Recruiting
Trial ID: NCT01987375
Purpose
This study is an open label, single institution, Phase 1 dose-escalation study to determine
the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell
carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a
dose of an approved head and neck cancer drug (Cetuximab) along with an investigational study
drug called Cetuximab-IRDye800. Cetuximab-IRDye800 is a drug that is given prior to surgery
that attaches to cancer cells and appears to make them visible to the doctor when he uses a
special camera during the operation. The investigators are evaluating whether or not the use
of the study drug along with the special camera will better identify the cancer while
patients are in the operating room.
Official Title
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Stanford Investigator(s)
Vasu Divi, MD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Davud Sirjani, MD
Clinical Professor, Otolaryngology (Head and Neck Surgery)
John B. Sunwoo, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Eligibility
Inclusion Criteria:
1. Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
2. Patients diagnosed with any T stage, any subsite within the head and neck that are
scheduled to undergo surgical resection. Patients with recurrent disease or a new
primary will be allowed.
3. Planned standard of care surgery with curative intent for squamous cell carcinoma
4. Age ≥ 19 years
5. Have life expectancy of more than 12 weeks
6. Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
7. Have acceptable hematologic status, coagulation status, kidney function, and liver
function including the following clinical results:
- Hemoglobin ≥ 9gm/dL
- Platelet count ≥ 100,000/mm3
- Magnesium, potassium and calcium greater than or equal than the lower limit of
normal range per institution normal lab values
- TSH <10 micro International Units/mL
Exclusion Criteria:
1. Received an investigational drug within 30 days prior to first dose of
cetuximab-IRDye800
2. Had within 6 months prior to enrollment: MI, CVA, uncontrolled CHF, significant liver
disease, unstable angina
3. Inadequately controlled hypertension with or without current antihypertensive
medications
4. History of infusion reactions to cetuximab or other monoclonal antibody therapies.
5. Women who are pregnant or breast feeding
6. Patients who have a grade 2 or greater reaction with the test/loading cetuximab dose.
7. Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or
greater than 450 ms in females).
8. Lab values that in the opinion of the primary surgeon would prevent surgical
resection.
9. Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.
10. Patients with TSH>11
Intervention(s):
drug: Cetuximab-IRDye800
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061